[An explanation on "guiding principles of clinical research on mild cognitive impairment (protocol)"]

Insights

Mild cognitive impairment (MCI) research requires refined diagnostic criteria and validated neuropsychological scales. This review supports evidence-based guidelines for MCI diagnosis, incorporating clinical assessments and biological markers.

Area of Science:

  • Neurology
  • Geriatrics

Background:

  • Review of clinical criteria, subtypes, and diagnostic procedures for Mild Cognitive Impairment (MCI).
  • Evaluation of existing rating scales (CDR, GDS, ADAS-cog, IADL) for MCI definition and their limitations.
  • Emphasis on minimal impact on daily activities, with potential for subtle impairment in complex Instrumental Activities of Daily Living (IADL).

Discussion:

  • Comparison of Beijing United Study Group's principles with the European Alzheimer's Disease Consortium (EADC) criteria for MCI diagnosis.
  • Highlighting the EADC criteria's potential to better capture MCI syndrome heterogeneity.
  • Discussion on the role of diagnostic scales versus clinical criteria in MCI assessment.

Key Insights:

  • Neuropsychological scales like Mini-Mental State Examination (MMSE), Delayed Story Recall (DSR), Clock Draw Test (CDT), and Verbal Category Fluency Test (VCFT) are recommended for MCI screening with established cut-off scores.
  • Biological and neuroimaging markers, such as medial temporal lobe and hippocampal atrophy, are crucial for MCI detection.
  • Absence of major daily life repercussions is characteristic of MCI, though minimal impairment in complex IADL may be present.

Outlook:

  • Future research should focus on integrating clinical, neuropsychological, and biomarker data for robust MCI diagnosis.
  • Development of standardized protocols for MCI research based on evidence-based principles.
  • Continued refinement of diagnostic criteria to address the heterogeneity of MCI and its progression.

Related Concept Videos

Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Ethics in Research01:56

Ethics in Research

Today, scientists agree that good research is ethical in nature and is guided by a basic respect for human dignity and safety. However, this has not always been the case. Modern researchers must demonstrate that the research they perform is ethically sound.
Dementia l: Introduction01:22

Dementia l: Introduction

Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...